Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NBIX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,300 | $168.53 | $219.1K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,500 | $167.72 | $251.6K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,466 | $166.77 | $244.5K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 908 | $165.71 | $150.5K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,226 | $164.74 | $202.0K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 600 | $163.71 | $98.2K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 100 | $162.05 | $16.2K Sale | Form 4 ↗ |
| Nov 3, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 100 | $158.18 | $15.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,300 | $146.76 | $190.8K Sale | Form 4 ↗ |
| Nov 2, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 4,300 | $145.86 | $627.2K Sale | Form 4 ↗ |
| Nov 2, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,900 | $144.98 | $275.5K Sale | Form 4 ↗ |
| Oct 30, 2026 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 300 | $149.00 | $44.7K Sale | Form 4 ↗ |
| Sep 14, 2026 | David W. Boyer Chief Corp. Affairs Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 826 | $157.45 | $130.1K Sale | Form 4 ↗ |
| Sep 14, 2026 | Matt Abernethy Chief Financial Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 2,311 | $157.20 | $363.3K Sale | Form 4 ↗ |
| Sep 9, 2026 | Eric Benevich Chief Commercial Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 2,154 | $154.61 | $333.0K Sale | Form 4 ↗ |
| Jul 28, 2026 | Leslie V. Norwalk Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,250 | $182.01 | $227.5K Sale | Form 4 ↗ |
| Jul 10, 2026 | Ingrid Delaet Chief Regulatory Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 4,367 | $181.02 | $790.5K Sale | Form 4 ↗ |
| Jul 9, 2026 | Ingrid Delaet Chief Regulatory Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 8,433 | $178.72 | $1.5M Sale | Form 4 ↗ |
| Jul 9, 2026 | Darin Lippoldt Chief Legal Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 10,000 | $179.60 | $1.8M Sale | Form 4 ↗ |
| Jul 8, 2026 | Ingrid Delaet Chief Regulatory Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 2,737 | $178.54 | $488.7K Sale | Form 4 ↗ |
| Jul 7, 2026 | Ingrid Delaet Chief Regulatory Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 3,401 | $178.57 | $607.3K Sale | Form 4 ↗ |
| Jun 29, 2026 | Darin Lippoldt Chief Legal Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 1,690 | $170.81 | $288.7K Sale | Form 4 ↗ |
| Jun 29, 2026 | Darin Lippoldt Chief Legal Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 8,110 | $170.03 | $1.4M Sale | Form 4 ↗ |
| Jun 26, 2026 | Darin Lippoldt Chief Legal Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 200 | $169.57 | $33.9K Sale | Form 4 ↗ |
| Jun 5, 2026 | Stephen A. Sherwin Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,843 | $167.31 | $308.4K Sale | Form 4 ↗ |
| Jun 5, 2026 | Stephen A. Sherwin Director | NBIX Neurocrine Biosciences, Inc. | Sale | 5,829 | $166.56 | $970.9K Sale | Form 4 ↗ |
| Jun 5, 2026 | Stephen A. Sherwin Director | NBIX Neurocrine Biosciences, Inc. | Sale | 6,896 | $165.79 | $1.1M Sale | Form 4 ↗ |
| Jun 5, 2026 | Stephen A. Sherwin Director | NBIX Neurocrine Biosciences, Inc. | Sale | 2,549 | $164.44 | $419.2K Sale | Form 4 ↗ |
| Jun 5, 2026 | Stephen A. Sherwin Director | NBIX Neurocrine Biosciences, Inc. | Sale | 7,883 | $163.81 | $1.3M Sale | Form 4 ↗ |
| Jun 4, 2026 | Leslie V. Norwalk Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,250 | $168.06 | $210.1K Sale | Form 4 ↗ |
| Jun 2, 2026 | Julie Cooke Chief Human Resources Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 3,520 | $158.59 | $558.2K Sale | Form 4 ↗ |
| Jun 2, 2026 | Julie Cooke Chief Human Resources Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 9,521 | $157.62 | $1.5M Sale | Form 4 ↗ |
| Jun 2, 2026 | Julie Cooke Chief Human Resources Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 4,216 | $156.77 | $660.9K Sale | Form 4 ↗ |
| Jun 2, 2026 | Julie Cooke Chief Human Resources Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 5,466 | $155.46 | $849.7K Sale | Form 4 ↗ |
| Jun 2, 2026 | Julie Cooke Chief Human Resources Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 14,214 | $154.83 | $2.2M Sale | Form 4 ↗ |
| Jun 1, 2026 | Jude Onyia Chief Scientific Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 11,000 | $160.25 | $1.8M Sale | Form 4 ↗ |
| May 29, 2026 | Ingrid Delaet Chief Regulatory Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 2,261 | $156.71 | $354.3K Sale | Form 4 ↗ |
| May 27, 2026 | Jude Onyia Chief Scientific Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 11,000 | $155.53 | $1.7M Sale | Form 4 ↗ |
| May 26, 2026 | David W. Boyer Chief Corp. Affairs Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 3,888 | $156.64 | $609.0K Sale | Form 4 ↗ |
| May 19, 2026 | Kevin Charles Gorman Director | NBIX Neurocrine Biosciences, Inc. | Sale | 245,088 | $154.33 | $37.8M Sale | Form 4 ↗ |
| May 15, 2026 | Richard F. Pops Director | NBIX Neurocrine Biosciences, Inc. | Sale | 15,000 | $157.65 | $2.4M Sale | Form 4 ↗ |
| May 12, 2026 | Leslie V. Norwalk Director | NBIX Neurocrine Biosciences, Inc. | Sale | 3,810 | $155.01 | $590.6K Sale | Form 4 ↗ |
| Jan 16, 2026 | Kyle Gano Chief Executive Officer, Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,812 | $132.71 | $240.5K Sale | Form 4 ↗ |
| Jan 16, 2026 | Kyle Gano Chief Executive Officer, Director | NBIX Neurocrine Biosciences, Inc. | Sale | 34,588 | $132.70 | $4.6M Sale | Form 4 ↗ |
| Dec 16, 2025 | Leslie V. Norwalk Director | NBIX Neurocrine Biosciences, Inc. | Sale | 1,190 | $155.09 | $184.6K Sale | Form 4 ↗ |
| Dec 15, 2025 | Leslie V. Norwalk Director | NBIX Neurocrine Biosciences, Inc. | Sale | 5,000 | $152.23 | $761.1K Sale | Form 4 ↗ |
| Dec 8, 2025 | Darin Lippoldt Chief Legal Officer | NBIX Neurocrine Biosciences, Inc. | Sale | 4,376 | $159.65 | $698.6K Sale | Form 4 ↗ |
| Dec 3, 2025 | Gary A. Lyons Director | NBIX Neurocrine Biosciences, Inc. | Sale | 15,000 | $152.61 | $2.3M Sale | Form 4 ↗ |
| Nov 25, 2025 | George J. Morrow Director | NBIX Neurocrine Biosciences, Inc. | Sale | 15,000 | $143.37 | $2.2M Sale | Form 4 ↗ |
| Nov 5, 2025 | William H. Rastetter Director | NBIX Neurocrine Biosciences, Inc. | Sale | 18,000 | $151.82 | $2.7M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 9:22 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances